Allogeneic double‐negative T cell therapy for relapsed <scp>acute myeloid leukemia</scp> patients post <scp>allogeneic hematopoietic stem cell transplantation</scp>: A first‐in‐human phase I study

Baolin Tang(University of Science and Technology of China), Xiaoyu Zhu(Jiangsu Hengrui Medicine (China)), Pingping Teng(Beike Biotechnology (China)), Zimin Sun(University of Science and Technology of China), Wen Yao(University of Science and Technology of China), Aaron D. Schimmer(University of Toronto), Ping Qiang(University of Science and Technology of China), Xiandeng Chu(Anhui Medical University), Tianzhong Pan(University of Science and Technology of China), Zhiqiang Xiang(Beike Biotechnology (China)), Jong Bok Lee(University Health Network), Jian Wang(University of Science and Technology of China), Liming Yang(Hunan Children's Hospital), Liangquan Geng(University of Science and Technology of China), Guangyu Sun(University of Science and Technology of China), Dongyao Wang(University of Science and Technology of China), Huilan Liu(University of Science and Technology of China), Zhang Li(University of Toronto), Siqi Cheng(Nanjing Agricultural University), Mei‐Juan Tu(University of California, Davis)
American Journal of Hematology
April 6, 2022
Cited by 26


Related Papers